Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

9 Oct 2025 07:00

RNS Number : 6214C
Polar Capital Holdings PLC
09 October 2025
 

9 October 2025 Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides an update in respect of the three months to 30 September 2025.

 

Group AuM (unaudited)

 

Polar Capital reports that as at 30 September 2025 its AuM was £26.7bn compared to £23.2bn at the end of June 2025, an increase of 15% over the quarter. In the quarter, AuM increased by fund performance and market movements of £3.6bn, offset by net outflows of £58m.

 

AuM movement in three months to 30 September 2025

Open ended

Funds

(£m)

Investment

Trusts

(£m)

Segregated mandates

(£m)

Total

(£m)

AuM at 1 July 2025

 

17,259

 

5,457

448

23,164

Net flows

 

50

 

(74)

(34)

(58)

Market movement

and performance

 

2,596

 

911

87

3,594

Total AuM at

30 September 2025

 

19,905

 

6,294

501

26,700

 

AuM movement in six months to 30 September 2025

Open ended

Funds

(£m)

Investment

Trusts

(£m)

Segregated mandates

(£m)

Total

(£m)

AuM at 1 April 2025

15,994

 

4,846

569

21,409

Net flows

(386)

 

(117)

(187)

(690)

Corporate action1

 

-

 

(280)

-

(280)

Market movement

and performance

4,297

1,845

119

6,261

Total AuM at

30 September 2025

19,905

6,294

501

26,700

1 Return of capital to investors in June 2025 as the Polar Capital Global Financials Trust underwent a 100% tender offer following which 44% of issued capital was tendered.

 

 

Net performance fee profits (unaudited)

 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. There is no certainty that the fees will be sustained over the next quarter, as performance fees can be volatile.

 

Performance fees

net of staff allocations (All figures in £m)

Six months to

30 Sep 24

12 months to

31 Mar 25

(year-end)

Six months to

30 Sep 25

Received

-

7.9

-

Accrued in underlying funds with year ends on or before the financial year end

0.7

n/a

15.0*

Total net performance fee profits

0.7

7.9

15.0*

\* The figures exclude £1.5m of net performance fee distributions (staff allocations) that are deferred into future periods for accounting purposes, and which should be deducted from the total performance fee profit figure for the purposes of calculating adjusted total earnings per share.

 

Iain Evans, Chief Executive, commented:

"I am pleased to report that assets under management rose by 15% over the quarter to a new all-time high of £26.7bn, up from £23.2bn at the end of June. This £3.5bn increase reflected £3.6bn of positive fund performance and market movements and net outflows of £58m. 

 

"Equity markets have delivered robust returns so far this year, with enthusiasm around artificial intelligence continuing to drive major indices. Our meaningful exposure to technology has enabled us to benefit from this favourable backdrop.

 

"It is encouraging that the pace of redemptions has slowed significantly, with total net outflows of only £58m compared with net outflows of £632m in the prior quarter. Demand for our funds was broad-based, particularly across our higher-growth strategies. Those in net inflow included the Artificial Intelligence, Global Technology, Asian Stars, Emerging Market Stars, Biotechnology, Japan Value, Financial Credit, Global Absolute Return, Smart Energy, and International Small Company funds, which together generated £350m of net inflows during the quarter.

 

"Our European and UK strategies remained out of favour, with combined net outflows of £175m. The open-ended Global Technology Fund recorded net inflows of £226m compared to net outflows of £162m in the last quarter, having delivered a return 18% ahead of its benchmark calendar year to date. Elsewhere, the closure of an Emerging Market managed account was largely offset by the establishment of a new Biotechnology managed account, which was funded with an initial £93m by a U.S. endowment.

 

"At the Polar Capital Technology Trust AGM on 10 September 2025, shareholders voted overwhelmingly in favour of the Company's continuation, with approximately 99% of votes cast supporting the resolution.

 

"As I begin my tenure as CEO, I am proud to lead a firm that continues to demonstrate resilience and a clear sense of purpose. With signs emerging of a more supportive environment for active managers, Polar Capital is in a strong position as a specialist boutique. While macroeconomic uncertainty and investor caution persist, our focus remains on delivering long-term results for our clients and shareholders. Supported by significant fund capacity, improving performance across our active strategies, and the dedication of our talented teams, I am confident Polar Capital is well positioned for the years ahead."

 

 

For further information please contact:

 

Polar Capital

Iain Evans (Chief Executive)Samir Ayub (Chief Financial Officer)

+44 (0)20 7227 2700

 

Deutsche Numis - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

 

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

Thomas Philpott

 

 

+44 (0)20 3597 8680

Camarco - PR

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

+44 (0)20 3757 4980

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEASEPESFSFFA
Date   Source Headline
19th Mar 202012:03 pmRNSPrice Monitoring Extension
12th Mar 20208:37 amRNSIssue of Equity
2nd Mar 20207:00 amRNSTotal Voting Rights
28th Feb 20204:41 pmRNSSecond Price Monitoring Extn
28th Feb 20204:36 pmRNSPrice Monitoring Extension
21st Feb 202011:51 amRNSForm 8.3 - Redde PLC
21st Feb 20209:59 amRNSIssue of Equity
20th Feb 20201:54 pmRNSForm 8.3 - Redde PLC
18th Feb 202011:14 amRNSForm 8.3 - Redde PLC
18th Feb 202010:28 amRNSChange of Auditor
17th Feb 20202:44 pmRNSForm 8.3 - Redde PLC
13th Feb 20202:37 pmRNSIssue of Equity
13th Feb 20207:00 amRNSTeam Acquisition
7th Feb 20201:09 pmRNSForm 8.3 - Redde PLC
6th Feb 20202:45 pmRNSForm 8.3 - Redde PLC
5th Feb 20202:33 pmRNSForm 8.3 - Redde PLC
3rd Feb 202011:14 amRNSBlock listing Interim Review
28th Jan 20201:06 pmRNSForm 8.3 - Redde PLC
22nd Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
21st Jan 20202:26 pmRNSForm 8.3 - Redde PLC
21st Jan 20202:12 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20202:01 pmRNSForm 8.3 - Consort Medical PLC
20th Jan 20201:37 pmRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Redde PLC
17th Jan 202011:13 amRNSForm 8.3 - Consort Medical PLC
16th Jan 202012:28 pmRNSForm 8.3 - Redde PLC
16th Jan 202012:26 pmRNSForm 8.3 - Consort Medical PLC
15th Jan 202012:20 pmRNSForm 8.3 - Redde PLC
14th Jan 202012:00 pmRNSForm 8.3 - Redde PLC
13th Jan 20201:49 pmRNSForm 8.3 - Redde Plc
10th Jan 20201:09 pmRNSForm 8.3 - Redde Plc
9th Jan 20207:00 amRNSAuM Update
30th Dec 201912:35 pmRNSForm 8.3 - Redde PLC
24th Dec 201911:35 amRNSForm 8.3 - Redde PLC
23rd Dec 20193:24 pmRNSForm 8.3 - Redde PLC
20th Dec 201911:18 amRNSForm 8.3 - Redde PLC
19th Dec 20192:17 pmRNSForm 8.3 - Redde PLC
18th Dec 20191:42 pmRNSForm 8.3 - Consort Medical PLC
17th Dec 201910:58 amRNSForm 8.3 - Consort Medical Plc
17th Dec 20199:37 amRNSHolding(s) in Company
6th Dec 20191:09 pmRNSForm 8.3 - Consort Medical Plc
5th Dec 20192:24 pmRNSForm 8.3 - Consort Medical Plc
4th Dec 20191:22 pmRNSForm 8.3 - Consort Medical Plc
2nd Dec 20191:59 pmRNSForm 8.3 - Redde PLC
2nd Dec 20197:00 amRNSTotal Voting Rights
25th Nov 20197:00 amRNSUnaudited interim results
20th Nov 20194:40 pmRNSSecond Price Monitoring Extn
20th Nov 20194:35 pmRNSPrice Monitoring Extension
20th Nov 20191:52 pmRNSBlock Listing Application
20th Nov 20191:30 pmRNSCrystallisation of Business Unit & Issue of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.